Skip to content

Low-Dose sucrose for migraine prophylaxis ,and its impact on insulin receptor, CGRP and its receptor pathway gene methylation

Low-Dose sucrose for migraine prophylaxis ,and its impact on insulin receptor, CGRP and its receptor pathway gene methylation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008789
Enrollment
Unknown
Registered
2016-07-06
Start date
2016-07-11
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

High- dose group :13.5g oral-surcose per day
Medium- dose group:9g oral-surcose per day
Low- dose group:4.5g oral-surcose per day

Sponsors

School of Public Health,Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male or female non-premonitory migraine patients between 18-65 years old. 2. Diagnosed as migraine according to the diagnostic criteria specified by the International Classification of Headache Disorder, 3rd edition (beta version) and initial of age is less than 50 years old; 3. Migraine present for at least three years and patients having 2-6 attacks per month; 4. Moderate ti severe pain (VAS=3.6)which affected the work and learning; 5. No prophylactic drugs of migraine such as beta-blockerscalcium channel blockersantiepileptic drugs and son on were taken in the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Having analgesics more than 10 times due to the migraine attacks every month; 2. Special types of migraine such as ophthalmoplegia hemiplegic migraine type; 3. Cluster headache,tension-type headache and other secondary headache disorders; 4. Pregnancy and lactation women; 5. Combined with hepaticrenal hematopoietic system and other serous primary diseases ,hypertension and diabetes mellitus; 6. Having severe mental disease; 7. Allergic constitution; 8. Refused to sign the consent.

Design outcomes

Primary

MeasureTime frame
Change in the duration of migraine attack;change in the frequency of migraine attack;Headache days(days with more than 4h of headache irrespective of pain quality and associated symptoms);Migraine days (days with typical features of migraine);

Secondary

MeasureTime frame
Automatic days;Visual Analogue Scale;Blood sugar;Glycosylated hemoglobin (HbA1C);OGTT;The frequency of analgesics;life quality of migrainers;Headache impact test;the MIgraine Disability Assesment Quetstionaire;Headache accompanied symptoms;

Countries

China

Contacts

Public ContactYashuang Zhao

Harbin Medical University

zhao_yashuang@263.net+86 0451 87502823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026